Drug Trial Radar · NCT07538804
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
294
Planned (sponsor's estimate)
Start
Jul 10, 2026
Primary completion
Jun 30, 2029
Study completion Oct 30, 2029
Sponsor
- Lead sponsor
- Avistone Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
Conditions
- Non-Small Cell Lung Cancer
Interventions
ANS02Drug
4 dose levels would be explored during the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: From the time of first dose to 28 days post last dose of ANS02
- Incidence of Serious Adverse Events (SAEs)Time frame: From time of first dose to 28 days post last dose of ANS02
- Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: From time of first dose of ANS02 to end of DLT period (approximately 28 days)
- Incidence of baseline laboratory finding, ECG and vital signs changesTime frame: From time of first dose to 28 days post last dose of ANS02
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Fairfax, Virginia · Recruiting
Research Site
Guangzhou, Guangdong, China · Not yet recruiting
Research Site
Harbin, Heilongjiang, China · Recruiting
Research Site
Zhengzhou, Henan, China · Not yet recruiting
Study Site
Chengdu, Sichuan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.